Cited by 2,409Glioma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Response criteria for phase II studies of supratentorial malignant glioma.

Macdonald, D R, Cascino, T L, Schold, S C, Cairncross, J G·1990·Journal of Clinical Oncology

DOI 10.1200/jco.1990.8.7.1277

Open this paper in CoChat — free account

Abstract

We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.

Integrity signals

Registry

Crossref · 10.1200/jco.1990.8.7.1277

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 345
Self-citation
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J., & Wilson, C. B. (1977) · Journal of neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone, A., Longo, D. L., Vt, D., Ihde, D. C., Duffey, P. L., Jaffe, E. S., Solomon, D., HUBBARD, S. M., & Young, R. C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1832 · Cited by 178
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas
Chamberlain, M. C., Murovic, J. A., & Levin, V. A. (1988) · Neurology · doi:10.1212/wnl.38.9.1371 · Cited by 149
Steroid‐induced CT changes in patients with recurrent malignant glioma
Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100
Self-citation
Computerized tomography in the prognosis of malignant cerebral gliomas
Murovic, J. A., Turowski, K., Wilson, C. B., Hoshino, T., & Levin, V. A. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.6.0799 · Cited by 42
Criteria and definitions for response and relapse in children with brain tumors
Zeltzer, P. M., Friedman, H. S., Norris, D. G., & Ragab, A. H. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7+ · Cited by 35
Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour
Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33
Self-citation
The accuracy of volumetric measurement of high-grade gliomas
Chisholm, R. A., Stenning, S. P., & Hawkins, T. D. (1989) · Clinical Radiology · doi:10.1016/s0009-9260(89)80007-8 · Cited by 32

Show all 11 references

Sorted by citations

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citation
3D Slicer as an image computing platform for the Quantitative Imaging Network
Fedorov, A., Beichel, R., Kalpathy–Cramer, J., Finet, J., Fillion‐Robin, J., Pujol, S., Bauer, C., Jennings, D. L., Fennessy, F., Milan Sonka, A., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.05.001 · Cited by 9,095
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,890
Self-citation
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,516
Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,597
Self-citation
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M. A., Butman, J. A., Camphausen, K. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,567
Cancer Research Communications
Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Martini, P., Sales, G., Beltrame, L., Clivio, L., Ceppi, L., Di Marino, M., et al. (2021) · doi:10.1158/1078-0432 · Cited by 1,537
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J. E., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,417
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
van den Bent, M. J., Brandes, A. A., TAPHOORN, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J., Bernsen, H. J. J. A., Frénay, M., Tijssen, C. C., Grisold, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,220
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Cairncross, G. J., Wang, M., Shaw, E., Jenkins, R. B., Brachman, D. G., Buckner, J. C., Fink, K., Souhami, L., Laperrière, N., Curran, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,152
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,136
Response assessment criteria for brain metastases: proposal from the RANO group
Lin, N., Lee, E. Q., Aoyama, H., Barani, I. J., Barboriak, D. P., Baumert, B. G., Bendszus, M., Brown, P. D., Camidge, D. R., Chang, S. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70057-4 · Cited by 1,099
Self-citation
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,094
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
A survey of MRI-based medical image analysis for brain tumor studies
Bauer, S., Wiest, R., Nolte, L.-P., & Reyes, M. (2013) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/13/r97 · Cited by 1,036
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
Abrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M. K., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 918
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
Sahm, F., Schrimpf, D., Stichel, D., Jones, D., Hielscher, T., Schefzyk, S., Okonechnikov, K., Koelsche, C., Reuß, D., Capper, D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30155-9 · Cited by 874
NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 841
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 808
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wick, W., Hartmann, C. J., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 803
Bevacizumab for recurrent malignant gliomas
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R. A., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 809
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R. Y., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 794
Standards of care for treatment of recurrent glioblastoma—are we there yet?
Weller, M., Cloughesy, T. F., Perry, J., & Wick, W. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos273 · Cited by 766
Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse
Yung, W. K. A., Prados, M. D., Yayá, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R. E., Olson, J. J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 756
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., TAPHOORN, M. J. B., Bernsen, H. J. J. A., Frénay, M., Tijssen, C. C., Grisold, W., Sipos, L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6078 · Cited by 745
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
Albert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C. J., Pope, W. B., Law, I. G., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 743
Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Cairncross, G. J., Berkey, B. A., Shaw, E., Jenkins, R. B., Scheithauer, B. W., Brachman, D. G., Buckner, J. C., Fink, K., Souhami, L., Laperierre, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3414 · Cited by 726
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
Lang, F. F., Conrad, C. A., Gomez‐Manzano, C., Yung, W. K. A., Sawaya, R. A., Weinberg, J. S., Prabhu, S. S., Rao, G., Fuller, G. N., Aldape, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.8219 · Cited by 718
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K. V., Boni, J. P., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 690
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
Ellingson, B. M., Bendszus, M., Boxerman, J. L., Barboriak, D. P., Erickson, B. J., Smits, M., Nelson, S. J., Gerstner, E. R., Alexander, B. M., Goldmacher, G., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 700
Diffusion Magnetic Resonance Imaging: an Early Surrogate Marker of Therapeutic Efficacy in Brain Tumors
Chenevert, T. L. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.2029 · Cited by 672
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y. L., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 661
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 651
The cerebrospinal fluid provides a proliferative niche for neural progenitor cells
Lehtinen, M. K., Zappaterra, M. W., Chen, X., Yang, Y. J., Hill, A. D., Lun, M., Maynard, T., Gonzalez, D., Kim, S., Ye, P., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.023 · Cited by 648
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
van den Bent, M. J., Wefel, J., Schiff, D., TAPHOORN, M. J. B., Jaeckle, K. A., Junck, L., Armstrong, T. S., Choucair, A. K., Waldman, A. D., Gorlia, T., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70057-2 · Cited by 641
Self-citation
Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response
Moffat, B. A., Chenevert, T. L., Lawrence, T. S., Meyer, C. R., Johnson, T. D., Dong, Q., Tsien, C. I., Mukherji, S. K., Quint, D. J., Gebarski, S. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501532102 · Cited by 639
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Batchelor, T. T., Mulholland, P. J., Neyns, B., Nabors, B., Campone, M., Wick, A., Mason, W. P., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 623
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Mao, Y. Q., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.024 · Cited by 609
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
Rampling, R. P., Cruickshank, G., Papanastassiou, V., Nicoll, J. A. R., Hadley, D. M., Brennan, D., Petty, R., MacLean, A. G., Harland, J., McKie, E. A., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301184 · Cited by 594
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clément, P. M., Frénay, M., Campone, M., Baurain, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 587
Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
da Cruz, L. C. H., Rodríguez, I., Domingues, R. C., Gasparetto, E. L., & Sorensen, A. G. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2397 · Cited by 551
Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96–07
Batchelor, T. T., Carson, K. A., O’Neill, A., Grossman, S. A., Alavi, J. Β., New, P., Hochberg, F. H., & Priet, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.036 · Cited by 549
Combined modality therapy for primary CNS lymphoma.
DeAngelis, L. M., Yahalom, J., Thaler, H. T., & Kher, U. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.635 · Cited by 533
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
Ostermann, S., Csajka, C., Buclin, T., Leyvraz, S., Lejeune, F. J., Decosterd, L. A., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0807 · Cited by 521
Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L., Mason, W. P., Weller, M., Hong, S., Musib, L. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 518
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
de Groot, J., Fuller, G. N., Kumar, A. J., Piao, Y., Eterovic, K. A., Ji, Y., & Conrad, C. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop027 · Cited by 508
Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review
Weinstein, J. S., Varallyay, C. G., Dosa, E., Gahramanov, S., Hamilton, B., Rooney, W. D., Muldoon, L. L., & Neuwelt, E. A. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.192 · Cited by 500
Glioblastoma
Wirsching, H., Galanis, E., & Weller, M. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00023-2 · Cited by 532
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 489
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
Reardon, D. A., Fink, K., Mikkelsen, T., Cloughesy, T. F., O’Neill, A., Plotkin, S. R., Glantz, M., Ravin, P. D., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 478
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Liau, L. M., Ashkan, K., Brem, S. S., Campian, J. L., Trusheim, J. E., IWAMOTO, F. M., Tran, D. D., Ansstas, G., Cobbs, C., Heth, J., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5370 · Cited by 479
Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
Taal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E. C., Swaak‐Kragten, A. T., Smitt, P. A. E. S., van Es, C. A., & van den Bent, M. J. (2008) · Cancer · doi:10.1002/cncr.23562 · Cited by 465
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U. S., Clément, P. M., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 453
O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Schoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Abu Hejleh, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.018 · Cited by 443
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen, W., Cloughesy, T. F., Kamdar, N. V., Satyamurthy, N., Bergsneider, M., Liau, L. M., Mischel, P. S., Czernin, J., Phelps, M. E., & Silverman, D. H. S. (2005) · PubMed · Cited by 437
Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.
Ino, Y., Betensky, R. A., Ƶlatescu, M. C., Sasaki, H., Macdonald, D. R., Stemmer-Rachamimov, A. O., Ramsay, D. A., Cairncross, J. G., & Louis, D. N. (2001) · PubMed · Cited by 432
Self-citation
Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy
Pels, H., Schmidt‐Wolf, I. G. H., Glasmacher, A. G., Schulz, H., Engert, A., Diehl, V., Zellner, A., Schackert, G., Reichmann, H., Kroschinsky, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.056 · Cited by 426
Response Assessment in Neuro-Oncology Clinical Trials
Wen, P. Y., Chang, S. M., van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 426
Self-citation
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L. M., Wang, Y., Peng, B., Abrey, L. E., Raizer, J. J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 424
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
Schuster, J. M., Lai, R. K., Recht, L. D., Reardon, D. A., Paleologos, N. A., Groves, M. D., Mrugała, M. M., Jensen, R. L., Baehring, J. M., Sloan, A. E., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou348 · Cited by 422
Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas
Fine, H. A., Figg, W. D., Jaeckle, K. A., Wen, P. Y., Kyritsis, A. P., Loeffler, J. S., Levin, V. A., Black, P. M., Kaplan, R. S., Pluda, J. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.708 · Cited by 421
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Lamborn, K. R., Yung, W. K. A., Chang, S. M., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., Fink, K., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-062 · Cited by 417
Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme
Freeman, A. I., Zakay‐Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.016 · Cited by 407
Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review
Kubben, P., ter Meulen, K. J., Schijns, O. E. M. G., ter Laak-Poort, M., van Overbeeke, J. J., & van Santbrink, H. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70130-9 · Cited by 415
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P. Y., Cloughesy, T. F., Greenberg, H. S., Schiff, D., Conrad, C. A., Fink, K., Robins, H. I., DeAngelis, L. M., Raizer, J. J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 396
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
Chen, W., Delaloye, S., Silverman, D. H. S., Geist, C. L., Czernin, J. G., Sayre, J. W., Satyamurthy, N., Pope, W. B., Lai, A., Phelps, M. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5825 · Cited by 391
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
van den Bent, M. J., Baumert, B. G., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clément, P. M., Baurain, J. F., Mason, W. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31442-3 · Cited by 399
Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status
Brandes, A. A., Tosoni, A., Franceschi, E., Sotti, G., Frezza, G., Amistà, P., Morandi, L., Spagnolli, F., & Ermani, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4969 · Cited by 383
RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
Schwartz, L. H., Seymour, L., Litière, S., Ford, R., Gwyther, S. J., Mandrekar, S. J., Shankar, L. K., Bogaerts, J., Chen, A. P., Dancey, J. E., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.082 · Cited by 393
Tumor-Treating Fields: A Fourth Modality in Cancer Treatment
Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D., & Von Hoff, D. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1117 · Cited by 380
Pseudoprogression and pseudoresponse in the treatment of gliomas
Brandsma, D., & van den Bent, M. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328332363e · Cited by 376
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372
Self-citation
Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., & Cairncross, J. G. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 372
Self-citation
Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas
Gutin, P. H., IWAMOTO, F. M., Beal, K. P., Mohile, N. A., Karimi, S., Hou, B. L., Lymberis, S. C., Yamada, Y. J., Chang, J., & Abrey, L. E. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.043 · Cited by 369
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
Dhermain, F. G., Hau, P., Lanfermann, H., Jacobs, A. H., & van den Bent, M. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70181-2 · Cited by 367
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
Sampson, J. H., Aldape, K., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq157 · Cited by 366
Corticosteroids in brain cancer patients: benefits and pitfalls
Dietrich, J., Rao, K., Pastorino, S., & Kesari, S. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.1 · Cited by 375
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A. P., Nebozhyn, M., Fantin, V. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0694 · Cited by 360
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
de Wit, M. Y., de Bruin, H. G., Eijkenboom, W. M. H., Smitt, P. A. E. S., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 356
Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1516 · Cited by 355
Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
D, R. P. M., Ricci‐Vitiani, L., Banna, G. L., Signore, M., Lombardi, D., Todaro, M., Stassi, G., Martini, M., Maira, G., Larocca, L. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0644 · Cited by 354
Multifunctional nanoparticles for brain tumor imaging and therapy
Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 359
Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies
Verma, N., Cowperthwaite, M. C., Burnett, M. G., & Markey, M. K. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos307 · Cited by 351
“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stupp, R., Tonn, J., Brada, M., & Pentheroudakis, G. E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq187 · Cited by 353
Perfusion MRI: The Five Most Frequently Asked Clinical Questions
Essig, M., Nguyen, T., Shiroishi, M. S., Saake, M., Provenzale, J. M., Enterline, D. S., Anzalone, N., Dörfler, A., Rovira, À., Wintermark, M., et al. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.9544 · Cited by 346
Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas
Fogh, S. E., Andrews, D. W., Glass, J., Curran, W. J., Glass, C., Champ, C. E., Evans, J. J., Hyslop, T., Pequignot, E. C., Downes, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6941 · Cited by 345
Carcinomatous meningitis: Leptomeningeal metastases in solid tumors
Chamberlain, M. C., Rhun, É. L., & Taillibert, S. (2013) · Surgical Neurology International · doi:10.4103/2152-7806.111304 · Cited by 342
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
van den Bent, M. J., Tesileanu, C. M. S., Wick, W., Sanson, M., Brandes, A. A., Clément, P. M., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J. F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00090-5 · Cited by 341
Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial
Yamanaka, R., Homma, J., Yajima, N., Tsuchiya, N., Sano, M., Kobayashi, T., Yoshida, S., Abe, T., Narita, M., Takahashi, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0120 · Cited by 325
Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors
Krop, I. E., Demuth, T., Guthrie, T., Wen, P. Y., Mason, W. P., Chinnaiyan, P., Butowski, N. A., Groves, M. D., Kesari, S., Freedman, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1540 · Cited by 321

Authors: Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G.
Affiliations: Western University (CA)
ORCID: Cairncross, J G
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1990-07
Volume: 8
Issue: 7
Pages: 1277-1280
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1990.8.7.1277
OpenAlex: W1959628099
Cited by: 2,409
References: 11
Citations by year: 2026: 31 · 2025: 21 · 2024: 36 · 2023: 52 · 2022: 53 · 2021: 59 · 2020: 68 · 2019: 75 · 2018: 97 · 2017: 111 · 2016: 125 · 2015: 122 · 2014: 161 · 2013: 186 · 2012: 145
FWCI: 3.90
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: high-grade glioma, supratentorial glioma, response criteria, tumor size measurement, complete response, partial response, stable disease, progressive disease, steroid use, neurologic findings, patient selection, magnetic resonance imaging, computed tomography
MeSH terms: Diagnostic Errors, Drug Evaluation, Glioma, Humans, Magnetic Resonance Imaging, Medical Oncology, Tomography, X-Ray Computed, Supratentorial Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Response criteria for phase II studies of supratentorial malignant glioma.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks